PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-22.17%
Both companies reducing R&D. Martin Whitman would check industry innovation trends.
-22.47%
Both companies reducing G&A. Martin Whitman would check industry cost trends.
No Data
No Data available this quarter, please select a different quarter.
-12.79%
Other expenses reduction while TRAW shows 0.00% growth. Joel Greenblatt would examine efficiency.
-22.23%
Both companies reducing operating expenses. Martin Whitman would check industry trends.
-22.23%
Both companies reducing total costs. Martin Whitman would check industry trends.
10981.63%
Interest expense change of 10981.63% while TRAW maintains costs. Bruce Berkowitz would investigate control.
-12.79%
Both companies reducing D&A. Martin Whitman would check industry patterns.
22.24%
EBITDA growth exceeding 1.5x TRAW's 9.48%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
22.23%
Operating income growth exceeding 1.5x TRAW's 9.50%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
-88.23%
Other expenses reduction while TRAW shows 61.88% growth. Joel Greenblatt would examine advantage.
18.34%
Pre-tax income growth exceeding 1.5x TRAW's 11.02%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
88.23%
Tax expense change of 88.23% while TRAW maintains burden. Bruce Berkowitz would investigate strategy.
18.34%
Net income growth exceeding 1.5x TRAW's 10.83%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
32.95%
EPS growth below 50% of TRAW's 100.00%. Michael Burry would check for structural issues.
32.95%
Diluted EPS growth below 50% of TRAW's 100.00%. Michael Burry would check for structural issues.
21.91%
Share count increase while TRAW reduces shares. John Neff would investigate differences.
21.91%
Diluted share increase while TRAW reduces shares. John Neff would investigate differences.